mRECIST for HCC: Performance and novel refinements

European Association for the Study of the Liver, 2018, EASL clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 69, 182, 10.1016/j.jhep.2018.03.019 Llovet, 2018, Molecular therapies and precision medicine for hepatocellular carcinoma, Nat Rev Clin Oncol, 15, 599, 10.1038/s41571-018-0073-4 Torre, 2015, Global cancer statistics, 2012, CA Cancer J Clin, 65, 87, 10.3322/caac.21262 Llovet, 2019, Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival, J Hepatol, 70, 1262, 10.1016/j.jhep.2019.01.028 Beaver, 2018, A 25-year experience of US food and drug administration accelerated approval of malignant hematology and oncology drugs and biologics, JAMA Oncol, 4, 849, 10.1001/jamaoncol.2017.5618 Kemp, 2017, Surrogate endpoints in oncology: When are they acceptable for regulatory and clinical decisions, and are they currently overused?, BMC Med, 15, 134, 10.1186/s12916-017-0902-9 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7 Cheng, 2013, Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial, J Clin Oncol, 31, 4067, 10.1200/JCO.2012.45.8372 Johnson, 2013, Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study, J Clin Oncol, 31, 3517, 10.1200/JCO.2012.48.4410 Cainap, 2015, Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial, J Clin Oncol, 33, 172, 10.1200/JCO.2013.54.3298 Zhu, 2015, SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 33, 559, 10.1200/JCO.2013.53.7746 Kudo, 2018, A randomised phase 3 trial of Lenvatinib vs. Sorafenib in firstline treatment of patients with unresectable hepatocellular carcinoma, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1 Vilgrain, 2017, Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Lancet Oncol, 18, 1624, 10.1016/S1470-2045(17)30683-6 Chow, 2018, SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-pacific patients with hepatocellular carcinoma, J Clin Oncol, 36, 1913, 10.1200/JCO.2017.76.0892 Qin, 2013, Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia, J Clin Oncol, 31, 3501, 10.1200/JCO.2012.44.5643 Abou-Alfa, 2016, Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance), J Clin Oncol, 34, 4_suppl Kudo, 2018, Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial, Lancet Gastroenterol Hepatol, 3, 424, 10.1016/S2468-1253(18)30078-5 Llovet, 2013, Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study, J Clin Oncol, 31, 3509, 10.1200/JCO.2012.47.3009 Zhu, 2014, Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial, JAMA, 312, 57, 10.1001/jama.2014.7189 Zhu, 2015, Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial, Lancet Oncol, 16, 859, 10.1016/S1470-2045(15)00050-9 Bruix, 2017, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 56, 10.1016/S0140-6736(16)32453-9 Rimassa, 2018, Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study, Lancet Oncol, 19, 682, 10.1016/S1470-2045(18)30146-3 Abou-Alfa, 2018, Cabozantinib in patients with advanced and progressing hepatocellular carcinoma, N Engl J Med, 379, 54, 10.1056/NEJMoa1717002 Zhu, 2019, Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 20, 282, 10.1016/S1470-2045(18)30937-9 Abou-Alfa, 2018, Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC), Ann Oncol, 29, 1402, 10.1093/annonc/mdy101 Merle, 2019, Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.Lancet, Gastroenterol Hepatol, 4, 454 Lencioni, 2010, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma, Semin Liver Dis, 30, 52, 10.1055/s-0030-1247132 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumours, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Lencioni, 2008, Guidelines for imaging focal lesions in liver cirrhosis, Expert Rev Gastroenterol Hepatol, 2, 697, 10.1586/17474124.2.5.697 Omata, 2017, Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update, Hepatol Int, 11, 317, 10.1007/s12072-017-9799-9 Heimbach, 2018, AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology, 67, 358, 10.1002/hep.29086 Marrero, 2018, Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases, Hepatology, 68, 723, 10.1002/hep.29913 Vogel, 2019, Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 30, 871, 10.1093/annonc/mdy510 Forner, 2009, Evaluation of tumour response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumours reliable?, Cancer, 115, 616, 10.1002/cncr.24050 Bruix, 2001, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver, J Hepatol, 35, 421, 10.1016/S0168-8278(01)00130-1 Llovet, 2008, Panel of Experts in HCC Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma, J Natl Cancer Inst, 100, 698, 10.1093/jnci/djn134 www.scopus.com (accessed June, 2019). Lencioni, 2016, Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC, The SPACE trial. J Hepatol, 64, 1090, 10.1016/j.jhep.2016.01.012 Kudo, 2014, Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial, Hepatology, 60, 1697, 10.1002/hep.27290 Vincenzi, 2015, Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with locoregional therapies: a literature-based meta-analysis, PLoS ONE, 10, 10.1371/journal.pone.0133488 EASL-EORTC Guidelines of clinical management of HCC, 2012, EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 56, 908, 10.1016/j.jhep.2011.12.001 Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival, Hepatology, 37, 429, 10.1053/jhep.2003.50047 Bruix, 2017, Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase 3 studies, J Hepatol, 67, 999, 10.1016/j.jhep.2017.06.026 Lencioni, 2017, Objective response by mRECIST as a predictor and potential surrogate endpoint of overall survival in advanced HCC, J Hepatol, 66, 1166, 10.1016/j.jhep.2017.01.012 Kudo, 2019, Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT), J Clin Oncol, 37 Meyer, 2017, mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs. sorafenib, Liver Int, 37, 1047, 10.1111/liv.13359 El-Khoueiry, 2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 389, 2492, 10.1016/S0140-6736(17)31046-2 Zhu, 2018, Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial, Lancet Oncol, 19, 940, 10.1016/S1470-2045(18)30351-6 Ellis, 2014, American society of clinical oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes, J Clin Oncol, 32, 1277, 10.1200/JCO.2013.53.8009 Lencioni, 2013, New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma, Clin Cancer Res, 19, 1312, 10.1158/1078-0432.CCR-12-3796 Vouche, 2014, Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy, Hepatology, 60, 192, 10.1002/hep.27057 Seyal, 2015, Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma, Hepatology, 62, 1111, 10.1002/hep.27915 Llovet, 2019, A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (UHCC): updated results. ESMO Congress 2019. Barcelona (Poster), Ann. Oncol, 30, 253 Stein, 2018, Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC), J Clin Oncol, 36, suppl, 10.1200/JCO.2018.36.15_suppl.4074 Oxnard, 2016, Response rate as a regulatory end point in single-arm studies of advanced solid tumours, JAMA Oncol, 2, 772, 10.1001/jamaoncol.2015.6315 Cabibbo, 2013, Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response, PLoS ONE, 8, 10.1371/journal.pone.0070016 Gillmore, 2011, EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization, J Hepatol, 55, 1309, 10.1016/j.jhep.2011.03.007 Kim, 2013, Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation, Eur J Cancer, 49, 826, 10.1016/j.ejca.2012.08.022 Jung, 2013, Comparison of the methods for tumour response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization, J Hepatol, 58, 1181, 10.1016/j.jhep.2013.01.039 Prajapati, 2013, mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE), Ann Oncol, 24, 965, 10.1093/annonc/mds605 Hudes, 2007, Temsirolimus, interferon alpha or both for advanced renal cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838 Karapetis, 2008, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N Engl J Med, 359, 1757, 10.1056/NEJMoa0804385 Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumours: immune-related response criteria, Clin Cancer Res, 15, 7412, 10.1158/1078-0432.CCR-09-1624 Nishino, 2013, Developing a common language for tumour response to immunotherapy: immune-related response criteria using unidimensional measurements, Clin Cancer Res, 19, 3936, 10.1158/1078-0432.CCR-13-0895 Bohnsack, 2014, Adaptation of the immune-related response criteria: irRECIST, Ann Oncol, 25, iv361 Seymour, 2017, RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, 18, e143, 10.1016/S1470-2045(17)30074-8 Hodi, 2018, Immune-modified response evaluation criteria in solid tumours (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy, J Clin Oncol, 36, 850, 10.1200/JCO.2017.75.1644 Patt, 2019, Don't throw away RECIST 1.1 quite yet, Radiology, 291, 268, 10.1148/radiol.2019182669 Moehler, 2019, Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE), OncoImmunology, 8, 1615817, 10.1080/2162402X.2019.1615817 Heo, 2013, Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer, Nat Med, 19, 329, 10.1038/nm.3089 Eisenhauer, 2009, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Reig, 2013, Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design, Hepatology, 58, 2023, 10.1002/hep.26586 Iavarone, 2015, Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib, Hepatology, 62, 784, 10.1002/hep.27729 Lencioni, 2006, European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB). Impact of European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) guidelines on the use of contrast agents in liver ultrasound, Eur Radiol, 16, 1610, 10.1007/s00330-005-0123-z Chernyak V, Sirlin CB (Eds). The LI-RADS v2018 manual. www.acr.org. U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Clinical trial imaging endpoint process standards. Guidance for industry. April 2018. www.fda.gov. Shim, 2012, Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma, J Hepatol, 56, 406, 10.1016/j.jhep.2011.04.028 Kim, 2013, Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization, Clin Cancer Res, 19, 1503, 10.1158/1078-0432.CCR-12-2721 Hatano, 2019, alSteatotic and nonsteatotic scirrhous hepatocellular carcinomas reveal distinct clinicopathological features, Hum Pathol., 86, 222, 10.1016/j.humpath.2018.11.024 Shim, 2012, Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models, Radiology, 262, 708, 10.1148/radiol.11110282 Shim, 2013, Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria, J Vasc Interv Radiol, 24, 316, 10.1016/j.jvir.2012.10.022 Schwartz, 2009, Evaluation of lymph nodes with RECIST 1.1, Eur J Cancer, 45, 261, 10.1016/j.ejca.2008.10.028 Dodd, 1997, Enlarged abdominal lymph nodes in end-stage cirrhosis: CT-histopathologic correlation in 507 patients, Radiology, 203, 127, 10.1148/radiology.203.1.9122379 Luca, 2012, Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis, Radiology, 265, 124, 10.1148/radiol.12112236 Bruix, 2011, Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques, Hepatology, 54, 2238, 10.1002/hep.24670 Lencioni, 2011, Evolving strategies in the diagnosis of hepatocellular carcinoma, J Hepatol, 54, 184, 10.1016/j.jhep.2010.07.050 Tovoli, 2018, Inter-operator variability and source of errors in remarkabletumour response assessment for hepatocellular carcinoma treated with sorafenib, Eur Radiol, 28, 3611, 10.1007/s00330-018-5393-3 Jeon, 2018, Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumours in patients treated with sorafenib, Liver Int, 38, 1655, 10.1111/liv.13731 Korean Liver Cancer Association; National Cancer Center, 2019, 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma, Gut Liver, 13, 227, 10.5009/gnl19024